4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Cachexia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 83 ongoing clinical trials involving Cachexia
Of the 83 trials,34 trials are in Phase II
Furthermore, 33 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Cachexia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Cachexia, a musculoskeletal disorder. The largest number of ongoing clinical trials for Cachexia is conducted in the Asia-Pacific region. North Americaand Europe are among some of the other prominent regions involved in Cachexia-related drug trials.

Pfizer Inc: The leading ongoing Cachexia related clinical trialsponsor

Pfizer Incis the top sponsor for Cachexia-related ongoing clinical trials.

Shanghai Jiao Tong University, Helsinn Group, Kyunghee University Medical Center, and Shanghai Putuo District Center Hospitalare a few other notable clinical trial sponsors involved inCachexia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Cachexia

Megestrol Acetate,Medroxyprogesterone acetate (Provera, Ralovera, Progevera, Depo-Provera, Farlutal, Sayana, Sayana Press, Meprogest, Premtone, Depocon, Depo-Provera CI, Premelle, Provera-Pak, Elashine, Empeea, Medroxyprogesterone Acetate Greenstone), and Betamethasone sodium phosphate (Celestone, Celestene, Diprofast, Solu-Celestan) are among the key marketed drugs involving Cachexia.

Megestrol Acetate is a synthetic derivative of the naturally occurring steroid hormone, progesterone. It functions via Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR) Agonist mechanism of action. It is formulated as suspension and tablets for oral route of administration. Megestrol Acetate oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). Megestrol Acetate tablets is used for the palliative treatment of advanced carcinoma of the breast or endometrium. It was first approved in 1988 and is sold in the US by Par Pharmaceutical Holdings Inc.

Medroxyprogesterone acetate (Provera, Ralovera, Progevera, Depo-Provera, Farlutal, Sayana, Sayana Press, Meprogest, Premtone, Depocon, Depo-Provera CI, Premelle, Provera-Pak, Elashine, Empeea, Medroxyprogesterone Acetate Greenstone) is a synthetic progestogen hormone. It functions via Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR) Agonist mechanism of action. It is formulated as tablets, granules, suspension and powder for suspension for oral route of administration and formulated as solution or suspension for intramuscular, intravenous and subcuteneous route of administration. Medroxyprogesterone acetate is marketed for the treatment of Pain, Breast Cancer, Prostate Cancer, Female Contraception, Renal Cell Carcinoma, Dysmenorrhea, Menstrual Disorders, Hormone Refractory Breast Cancer, Hormone Sensitive Breast Cancer, and Endometriosis. It was first approved in 1959 and is marketed globally including the US, the UK, France, Germany, and China by several prominent pharma giants including Pfizer Inc, and Pharmacia LLC.